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The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration
Elisabeth L. Easley, D.M.D., M.P.H.
University of Nebraska, 2016
Advisor: Joseph B. Bavitz, D.M.D.
Purpose: Platelet rich fibrin (PRF) has been postulated to aid in regeneration. Therefore, the
purpose of this study is to evaluate the inflammatory response of PRF in vitro, and analyze
clinically and histologically the effectiveness of PRF on pulpal regeneration after reimplantation.
Materials and Methods: The in vivo experiment included 18 patients (69 teeth). Teeth were
extracted and apicoectomy performed. The tooth was reimplanted and splinted after PRF was
condensed into the apex. Control teeth received the same treatment with the exception of the
PRF. After 3-11 months, vitality was checked, teeth were extracted and analyzed histologically.
For the in vitro, PRF was fabricated from two donors. A periodontal ligament (PDL) cell
line was divided into four groups: A: PDL cells and PRF, B: PDL cells, PRF, and
Lipopolysaccharide (LPS), C: PDL cells and LPS, and D: PDL cells only. After 24 h LPS was
added to groups B and C. Supernatants were collected at 24, 48 and 72 h and an enzyme-linked
immunosorbent assay was used to measure the concentration of IL-6.
Results: PRF had no effect on diagnostic tests or histological outcome. Out of mouth time lead to
more post-operative non-vital responses. For the cell cultures, PRF synergized with LPS inducing
higher IL-6 release.
Conclusions: PRF does not improve vitality responses in vivo and results in higher expression of
IL-6 from PDLs.
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CHAPTER 1: INTRODUCTION
Pulpal necrosis after reimplantation, in either avulsion or autotransplantation, is a clinical
complication. If the pulp tissue is not regenerated, or if endodontic therapy is not performed, the
pulp space can become infected (Tronstad 1988). It has been suggested that treatment strategies
should attempt to limit peri-radicular inflammation therefore promoting favorable cemental
healing, pulpal revascularizaion, and limiting unfavorable osseous replacement (Trope, 2002).
To achieve regeneration of the dental pulp, three main elements are required. The first
element is a source of cells that are capable of differentiating into the desired tissue (Hargreaves
et al., 2013). Stem cells have been reported in both the dental pulp and the apical papilla
(Nakashima & Akamine, 2005; Huang et al., 2008). The second element is the presence of
growth factors and other tissue-inducing mediators. The third element is a scaffold, or a three
dimensional tissue structure that regulates the release of the growth factors (Hargreaves et al.,
2013). These characteristics drive the investigation for an ideal medium capable of promoting
endodontic revascularization and eventually the potential for regeneration of avulsed or
autotransplanted mature teeth. In a review article on pulpal regeneration of permanent teeth,
Haregreaves et al. (2008) suggested that platelet concentrates may be a promising material for
endodontics as they possess the characteristics required to achieve regeneration.
Platelet rich fibrin (PRF) is a second generation platelet concentrate that allows the
clinician to obtain fibrin membranes enriched with platelets and growth factors from an
anticoagulant-free blood harvest and without the addition of artificial biochemical modification
(Dohan et al., 2006). PRF has demonstrated clinical relevance through its ability to stimulate cell
proliferation of osteoblasts, gingival fibroblasts, and PDL cells. In addition, the PRF membrane
includes VEGF, a potent stimulator of angiogenesis. These properties make it a favorable product
for surgical procedures where revascularization is desirable (Tsai et al., 2009).
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To date, no human studies have been performed evaluating the effectiveness of PRF on
pulpal revascularization after reimplantation. Additionally, only histological evidence of the
benefits of PRF has been demonstrated in animal models. Peters (2014) discussed the need for a
broader spectrum of inclusion for cases attempting regeneration. Currently it is mostly limited to
immature teeth with larger apical foramina. The article emphasizes the need to expand the
evaluation of endodontic regeneration potential in mature teeth. Additionally, a further
understanding of PRF’s role in modulating inflammation is needed. A human trial evaluating PRF
as an adjunct to endodontic regeneration could offer more insight on its potential for inducing
pulpal regeneration of necrotic teeth. If PRF is capable of promoting regeneration in mature teeth,
the potential benefits include limiting the need for endodontic therapy following tooth avulsion,
potential for mature tooth transplantation in situations of congenitally missing teeth, and
utilization of PRF in endodontic regeneration therapy of mature necrotic teeth.
The purpose of this study is to evaluate the inflammatory response of PRF in vitro, and
analyze clinically and histologically the effectiveness of PRF on pulpal regeneration after
reimplantation. The central hypothesis of this study is that PRF has anti-inflammatory properties
that can aid in pulpal regeneration during reimplantation procedures or in cases of avulsion. The
second hypothesis is that introducing PRF into the apical foramen during autotransplanation will
enhance the regeneration of the pulpal tissue and improve clinical vitality results. Both
hypotheses will be tested through the following aims:
1) Evaluate the PDL cell inflammatory response to LPS through measurement of IL-6
cytokine in the presence of PRF
2) Determine if PRF effects the clinical vitality of an extracted and reimplanted tooth by
measuring responses to percussion, cold, and electric pulp test (EPT)
3) Evaluate histologically the inflammatory infiltrate and presence or absence of
vascularity in the pulp chambers and canals of the teeth treated with or without PRF
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CHAPTER 2: LITERATURE REVIEW
Regenerative endodontics: mature tooth avulsion
Dental trauma occurs frequently in children with an estimated 4-59% prevalence of
dental trauma around the world. This oral trauma frequently leads to pulpal necrosis (Gelndor &
Andreasen, 2007). Approximately 92% of avulsion cases of traumatized permanent teeth leads to
pulpal necrosis (Borum & Andreasen, 2001). This necrotic tissue is at high risk for bacterial
contamination. If the pulp tissue does not revascularize or if endodontic therapy is not performed,
the pulp space can become infected (Tronstad, 1988). It has been suggested that treatment
strategies should attempt to limit peri-radicular inflammation, therefore promoting favorable
cemental healing, pulpal revascularizaion, and limiting unfavorable osseous replacement (Trope,
2002). Whole pulp regeneration is considered the reconstitution of viable tissue in a space that
was previously avascular (Peters, 2014).
Regenerative endodontics is the formation and delivery of tissues to replace pulp that has
been traumatized or is diseased or absent (Murray et al., 2007). Clinical endodontic regenerative
treatment is still considered a challenge even for immature teeth, and for mature teeth is an area
of endodontics where more research is needed. Regenerative endodontics has been mostly
focused on immature teeth as they have a greater chance for pulpal regeneration; however, some
case studies suggest potential to expand the practice to mature necrotic teeth. Payani & Kim
(2013) published two case reports where a modified regenerative endodontic procedure was
utilized in place of conventional endodontics for traumatized mature teeth. They observed a
regression of the clinical symptoms and resolution of the apical radiolucency in both cases.
To achieve regeneration of the dental pulp, three main elements are required. The first
element is a source of cells that are capable of differentiating into the desired tissue (Hargreaves
et al., 2013). Stem cells have been reported in both the dental pulp and the apical papilla
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(Nakashima & Akamine, 2005; Huang et al., 2008). The second element is the presence of
growth factors and other tissue-inducing mediators. The third element is a scaffold, or a threedimensional tissue structure that regulates the release of the growth factors (Haregreaves et al.,
2013). These characteristics drive the investigation for an ideal medium capable of promoting
endodontic revascularization and eventually the potential for regeneration of avulsed or
autotransplanted mature teeth. In a review article on pulpal regeneration of permanent teeth,
Haregreaves et al. (2008) suggests that platelet concentrates may be a promising material for
endodontics as they possess the characteristics required to achieve regeneration.
Platelets and platelet concentrates: A history
Platelets, also referred to as thrombocytes, are a component of mammalian whole blood.
The function of platelets is primarily hemostasis through aggregation at an injured portion of a
blood vessel wall. Platelets are derived from bone marrow megakaryocytes, are discoidal
anucleate cytoplasmic fragments, and are on average 2-3 μm in diameter. They are not actually
true cells, in actuality they are circulating cell fragments. A normal platelet count for an adult
human is 1.5-4 thousand per µL in peripheral blood, and the average lifespan of a platelet is
approximately 8-10 days (Dohan et al., 2006). During tissue repair, platelets that have been
activated will release two different types of granules. The dense granules have serotonin,
adenosine triphosphotase, adenosine diphosphotase, and calcium (De Pascale et al., 2015).
Platelets also contain α-granules, a few mitochondria, and two prominent membrane structures.
The α-granules are spherical or oval structures with diameters ranging from 200-500 nm, each
enclosed within a membrane. These α-granules activate signaling proteins, which ultimately
result in gene expression for cellular proliferation, matrix formation, collagen synthesis, and
osteoid production (Gasling et al., 2009). The growth factors present in these α-granules exhibit
chemotactic and mitogenic properties which assist in promoting cell proliferation and modulating
cell functions that promote tissue healing and regeneration (Anitua et al., 2007)
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Platelet concentrations were first utilized in transfusion medicine for the prevention of
hemorrhage induced by severe thrombocytopenia (Dohan et al., 2008). The benefit of these
concentrates to assist in healing and stimulation of wound repair was initially explored through
the surgical application of fibrin glues. These glues consisted of concentrated fibrinogen (Matras
et al., 1970). The regenerative use for platelets was first described by Ross et al. in 1974. In this
study, Ross et al. (1974) demonstrated that platelet-poor plasma is much less effective than blood
serum in the proliferation of cultured monkey arterial smooth muscle. Addition of platelets to the
platelet-poor plasma increased activity; therefore, indicating a potential role of the platelet in
wound healing in vivo. Choukroun was the first to develop platelet rich fibrin, also termed
leukocyte and platelet-rich fibrin (L-PRF). Most platelet concentrate protocols lead to a lowdensity fibrin gel, which has benefits in surgical application due to pliability and ease of use;
however, it does not possess a true fibrin matrix. For the fibrin to be considered a biomaterial and
have potential healing effects, it must be a high density fibrin network.
Depending on the methods after collection of the whole blood, the result can lead to four
different platelet concentrate products. The concentrates that can be produced are pure plateletrich plasma (P-PRP), leukocyte-rich platelet rich plasma (L-PRP), pure platelet-rich fibrin (PPRF), and L-PRF (Dohan et al., 2009). The fabrication of P-PRP leads to a low platelet collection
as it attempts to avoid the collection of leukocytes which are usually found along with platelets in
the intermediate layer. The P-PRP procedure lacks consistency and the release of cytokines
occurs in a shorter duration than with PRF. With L-PRP the leukocytes which were previously
undesirable with fabrication of P-PRP are now included. The final product of L-PRP is rich in
leukocytes; however, it disintegrates quickly. Additionally, the machinery and biologics required
to fabricate L-PRP make it an expensive and time-consuming process (Dohan et al., 2009). PPRF is leukocyte poor and has to be mixed with an anticoagulant and separation gel.
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This process is both difficult to execute and the equipment needed is expensive. Finally, L-PRF
(or Choukroun’s PRF) is a simple and free technique that was developed to minimize blood
handling and remove the need for additives.
Characteristics of L-PRF:
L-PRF, or from here simply referred to as PRF, derives from a natural and progressive
polymerization occurring during the centrifugation of the blood without any additives
(Choukroun et al., 2001; Dohan & Choukroun, 2006). Without anticoagulants, fibrin
polymerization begins immediately after collection. This slow and natural polymerization process
of the fibrin results in a 3-dimensional and homogenous matrix during the centrifugation process
(Dohan et al, 2006). This polymerization and centrifugation leads to a strong, yet flexible and
elastic fibrin matrix with platelet cytokine and glycan chains embedded within the fibrin meshes
(Khiste & Tari, 2013). After centrifugation is complete, three layers are formed: the red blood cell
or corpuscle layer, the acellular plasma layer on top and the fibrin clot in the middle. The strong
fibrin matrix has a three-dimensional architecture where most of the platelets and leukocytes are
concentrated (Dohan et al., 2009). Fabrication of the PRF involves drawing whole blood into two
10 ml glass tubes and immediately centrifuging at 2700-3000 rpm for 10-12 minutes. This
process results in the three layers previously discussed. As the blood begins to coagulate during
the collection process, rapid handling is essential (Gupta et al., 2011). The diagram below
demonstrates the three different layers that are obtained after centrifugation.
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Figure 1: PRF Layers After Centrifugation
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There are numerous benefits to not discarding the leukocytes, as is done with P-PRF
(Dohan et al. 2009). Firstly, the presence of leukocytes promotes the in vivo recruitment of new
leukocytes aiding in inflammation and tissue repair (Zumstein et al., 2012). Regarding the
obvious anti-infectious role, leukocytes and monocytes present in the PRF (or recruited from invivo activation) contain high levels of myeloperoxidase, which is toxic to bacteria (Everts et al.,
2006). The combination of inductive and antimicrobial properties has made many advocate its use
in non-healing wounds. Platelet concentrate antimicrobial activity against Staphylococcus aureus
was shown to be equivalent to gentamicin and oxacillin and additionally was shown to have
significant effects in reducing the growth of Escherichia coli (Bielecki et al., 2007). The
synergistic antibacterial effect of both leukocytes and platelets yield supreme potential for
antimicrobial activity. Platelet α-granules contain not only growth factors and antimicrobial
peptides, but also catecholamines, serotonin, osteonectin, von Willebrand factor, proaccelerin,
and other substances. (Anitua et al., 2005; Bielecki et al., 2006; Slater et al., 1995). These are
released in high concentrations after platelet aggregation and may have antibacterial effects
(Bielecki et al., 2007). Additional benefits to preserving leukocytes is that they produce large
amounts of VEGF, which fosters healing and stimulates angiogenesis (Dohan et al., 2009;
Nielsen et al., 2001; Werther et al., 2002). As a decrease in vascularity is seen with age, having a
higher leukocyte count assists in higher levels of vascular endothelial growth factor (VEGF),
which assists in the induction of new vessel growth (Zumstein et al., 2012). This angiogenesis
potential is further promoted by the fibrin structure as fibrin induces healing after 4 days, in
addition to cellular interactions and angiogenesis by replacement of the fibrin by capillaries
(Butler et al., 2008; Laurens & Koolwijk, 2006).
PRF has been shown to be efficient in cell migration, proliferation, and cicatrisation
(Bensaid et al., 2003; Laurens & Koolwijk, 2006). Using platelet concentrations in wound healing
for either hard or soft tissue is mediated by a wide range of signaling proteins and intra and
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extracellular events (Gasling et al., 2009). Activation and degranulation of the α-granules releases
cytokines interleukin (IL)-1β, IL-6, TNF-α and growth factors TGF β1, PDGF, VEGF, EGF
which initiate healing through stimulating cell migration and proliferation (Dohan et al., 2006).
Dohan et al. (2006) suggests that through these cell mediators, PRF may act as an immune
regulator and decrease some of the harmful effects of inflammation of surrounding tissues during
wound healing. Below is a table adapted from information in Hotwani & Sharma (2014)
describing the growth factors and cytokines identified in PRF and their role in inflammation and
wound healing.
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Table 1: List of cytokine/growth factors present in PRF
IL-1

Stimulates T-helper cells, inflammatory
mediator

IL-6

B cell differentiation, T cell activator,
antibody secretion stimulation,
inflammatory and remodeling mediator

IL-4

Proliferation and differentiation of
activated B cells, moderates inflammation,
increases fibroblast synthesis of fibrillary
collagen

TNF-α

Monocyte activator, stimulate fibroblast
remodeling, increase phagocytosis and
neutrophil toxicity, modulates IL-1 and IL6 expression

VEGF

Initiates angiogenesis

TGF β1

Significant synthesis of collagen and
fibronectin

PDGF

Regulates migration, proliferation and
survival of mesenchymal cell lineages,
cicatrisation

IGFs 1 and 2

Mediator in apoptosis, chemotactic effects
towards human osteoblasts

11

These growth factors are released from platelets when activated by a stimulus or
aggregated by activators (Kaplan et al. 1978). A brief review of the cytokines and growth factors
present in a PRF membrane will demonstrate its influence in wound healing. IL-1, an
inflammatory mediator, activates osteoclasts and inhibits bone formation. TNF-α stimulates
fibroblasts and monocytes and modulates IL-1 and IL-6 (Gupta et al., 2011). IL-4 promotes
healing by modulating inflammation, increasing collagen synthesis and inhibiting MMPs.
Through the presence of IL-4, it is suggested that PRF prevents the production of IL-1β, TNF-α,
and prostaglandins when presented with bacterial endotoxin. TGF-β1 is a strong fibrosis agent
inducing collagen and fibronectin synthesis. PDGF assists in the production of cicatricial tissue as
wound healing progresses. IGFs instigate osteoblast activation and mediate apoptosis (Gupta et
al., 2011). VEGF is a powerful vascular endothelial growth factor, which initiates angiogenesis
and is capable of directing and redefining the network growth (Dohan et al., 2006). In fact, the
release of pro inflammatory cytokines IL-1β, IL-6 and TNF-α along with anti-inflammatory
cytokine IL-4 from PRF additionally accelerate angiogenesis (Schmid et al., 1997).
Characteristics of PRF: An emphasis on IL-6
The presence of IL-6 in PRF, and PRF’s ability to induce IL-6 release from surrounding
tissue, is of particular interest. IL-6 is a potent stimulator of inflammation, and therefore a good
marker for determining a material’s pro- and anti-inflammatory potential. IL-6 is a pleiotropic
cytokine that provokes both cellular and physiological responses on a broad spectrum. These
responses include, but are not limited to: inflammation, immune response, hematopoiesis, gene
activation, and proliferation, survival, and differentiation (Hirano et al., 1990). IL-6, along with
other pro-inflammatory cytokines like IL-1β, TNF- α, and TGF-β, are produced by many cell
types in the body (Gabay, 2006). IL-6 is produced at the site of inflammation and is a key player
in the acute phase response as well as the transition into chronic inflammation.
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IL-6 expression can be stimulated by IL-1, bacterial endotoxin, TNF-α, and PDGF. IL-6 acts as a
major amplifier for immune cells and leads to a combined response of destruction, inflammation,
and remodeling (Dohan, 2006).
While IL-6 is produced by a variety of human cells, the IL-6 receptor (IL-6R) is
expressed on few cells, namely hepatocytes, monocytes, B cells, a subset of T cells, and
neutrophils (Barnes et al., 2011). IL-6 principally induces responses from fibroblasts, endothelial
cells, and monocytes (Dohan 2006). At inflammatory sites the most important sources of these
pro-inflammatory cytokines are monocytes and macrophages. IL-6 has dual roles as it can act as a
defense mechanism by aiding in acute inflammation, but in chronic inflammation it is considered
pro-inflammatory. (Gabay, 2006). IL-6 is important for the transition from acute inflammation
into a chronic state by primarily changing the nature of the leukocyte infiltrate. This is
accomplished by altering the neutrophil population as well as by inducing the differentiation of
monocytes to macrophages (Mitani et al., 2000). By investigating the responses of these cells to
IL-6, it becomes apparent that IL-6 is a major player in both acute and chronic inflammation.
Acute inflammation is a limited physiological response that requires resolution in a short
period of time and in a localized area. If this is improbable, chronic inflammation will follow.
During this phase, IL-6 can have a protective effect by suppressing pro inflammatory cytokine
levels without compromising levels of anti-inflammatory cytokines (Xing et al., 1998; Kaplanski
et al., 2003). It additionally stimulates IL-1 receptor antagonist, an anti-inflammatory mediator.
Therefore, offering some prolongation of the acute phase (Gabay et al., 1997). Acute
inflammation is represented by a leukocyte infiltrate that is primarily neutrophilic (Gabay, 2006).
Endothelial cells (the epithelial lining of blood vessels) and fibroblasts (a connective tissue cell)
do not express IL-6R, but rather, interact with IL-6 via trans-signaling (utilizing a soluble
receptor) (Romano et al., 1997). IL-6 plays a role in angiogenesis through stimulation of
fibroblasts. As a profibrogenic cytokine, it has been shown to increase fibroblast proliferation,

13

collagen production, tissue inhibitor of metalloproteinases-1 (TIMP-1), and regulate the
expression of VEGF (Mihara et al., 1995). This can assist in modulating the amount of tissue
destruction occurring during inflammation, as well as encourage healing and vessel proliferation.
Activation of endothelial cells via trans-signaling leads to expression of various adhesion
molecules, including intercellular adhesion molecule 1, which promote leukocyte migration to the
site, and the release of chemokines like IL-8, which induces neutrophil migration. Additionally,
IL-6 stimulates endothelial cells and fibroblasts to produce more IL-6, creating a positive
autocrine feedback system. In this manner, IL-6 assists early on in promoting leukocyte, namely
neutrophil, chemotaxis to the area of infection; however, as the process matures, IL-6 encourages
a shift to chronic inflammation (Barnes et al., 2011).
Monocytes are white blood cells that can differentiate into macrophages or dendritic cells
depending on cytokine stimulation (Mitani et al., 2000). Once inflammation has progressed to a
chronic state, additional tissue damage begins occurring. After 24 to 48 hours the transition to
chronic inflammation histologically reveals primarily monocytes and lymphocytes. Since IL-6
encourages end-stage B lymphocyte differentiation (into plasma cells), immunoglobulin
secretion, and T lymphocyte proliferation and differentiation, it is therefore a key modulator in
the progression to the chronic inflammatory state (Gabay, 2006). IL-6 has been demonstrated to
favor the proliferation of Th1 cells (T helper cell that act primarily against bacteria and protozoa)
and to contribute to IL-2 expression furthering chronic inflammation (Jones et al., 2005). By
promoting the maturation of B lymphocytes into plasma cells, IL-6 assists in inducing the
production of antibodies at the site of infection. This enhances lymphocyte migration to the area
of inflammation, propagates the chronic inflammatory state, and ultimately leads to an increase in
tissue destruction (Hirano, 1992). The length of this phase can also be influenced by IL-6 as it
dictates apoptotic clearance of leukocytes like neutrophils, monocytes, and lymphocytes (Jones et
al., 2005). IL-6 has been reported to induce neutrophil apoptosis while simultaneously rescuing
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T-cells from apoptosis, therefore propagating the shift from acute to chronic stages of
inflammation (Barnes et al., 2011). In this manner, IL-6 appears to be capable of dramatically
influence the nature of the immune response through dictation of recruitment, activation, and
apoptotic clearance of specific leukocyte subpopulations (Jones et al., 2005).
PRF application: Surgical benefits
During wound healing, endothelial cells, leukocytes, and platelets are important players
in the formation of the initial platelet plug during hemostasis, and later in tissue regeneration (De
Pascale et al., 2015). Historically, the first clinical application of a platelet-derived preparation
was with collagen embedded with platelet proteins placed in chronic leg ulcers. This product
stimulated vascularized connective tissue in the chronic wounds (Krupski et al., 1991; Ganio et
al., 1993). Once fabricated, PRF can be compressed between two damp gauze yielding a strong
membrane applicable in many surgical situations. It is thought that platelets are immediately
activated upon application and that growth factors are massively released during the first hours
after placement on the surgical site (Dohan et al., 2009). Unlike PRP, PRF does not dissolve
within hours after application, but instead begins the slow remodeling process and disintegration
of the fibrin complex. This slow resorption allows for a continuous release of the cytokines
embedded within this fibrin matrix. Dohan et al. (2008) demonstrated that over the course of 1
week, PRF membrane sustains a very significant slow release of key growth factors. This
suggests that the membrane stimulates its environment for a significant amount of time during its
remodeling phase.
PRF has become a valuable adjunct to surgery in both the medical and dental fields
through its combination of high efficiency platelet and leukocyte collection in a stable matrix,
along with activation of growth factors and preservation of tissue repairing cytokines. Many
studies advocate its use in rotator cuff and other orthopedic procedures for these very same
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characteristics (Bielecki et al., 2007; Zumstein et al., 2012). In oral surgery, it has many
recommended applications including: as a membrane, inclusion in implant placement, post
enucleation of large periapical lesions, surgical removal of impacted third molars and impacted
canines, and pre-prosthetic surgeries to enhance bone density and soft tissue healing (Saluja et al.,
2011; Sunitha & Munirathnam, 2008). Kawamura and Urist (1988) demonstrated that PRF may
act as a supportive matrix for bone morphogenetic protein as well. Chang et al. (2010) showed
that PRF can be utilized to modulate the expression of osteoprotegerin and osteoblast
proliferation. PRF has become a popular adjunct during bone grafting and other forms of
reconstructive surgery.
PRF application: Use in regenerative endodontics
PRF was determined to be an ideal medium for revascularization of pulpal tissue due to
the presence of major cytokines entrapped within the fibrin mesh. According to Dohan et al.
2006, an ELISA test was performed on PRF samples and the concentrations of five different
cytokines was compared within the PRF clot and the blood serum. It is suggested that the fibrin
mesh entraps these cytokines and as the fibrin degrades over time, it allows for slow release of
these cytokines into the surrounding tissues. In a study by He et al. (2009) PRP and PRF in
medium were evaluated to determine the release of TGF-β1 and PDGF over the course of 28
days. PRP was shown to release growth factors more rapidly but then concentrations declined.
PRF demonstrated a gradual release in growth factors and their activity was kept up for a longer
period of time compared to PRP. PRF exhibited a controlled and long-term release of growth
factors where the highest amount was measured at day fourteen. In comparison, PRP had a more
uncontrolled and short term release of the measured growth factors with its highest concentration
on the first day. Due to this slow release, the investigators observed stimulation of rat calvaria
osteoblasts from exudate of PRF but not PRP after day 14 (He et al., 2009). Additionally, Schar et
al. (2015) observed that in comparison to PRP, PRF in medium had a higher release of TGF-β1, a
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long-term release of growth factors, and was a stronger inducer of mesenchymal cell migration.
PRF also had marginally higher release of VEGF and IGF-1.
The intrinsic incorporation of cytokines within the fibrin mesh allows for their
progressive release over time (approximately 7-11 days), as the network of fibrin disintegrates
around it (Huang 2010). Due to the solid consistency of the fibrin network, PRF membranes are
slowly destroyed by a remodeling process, similar to a natural blood clot (Clark, 2001). The
platelet cytokines that are gradually released as the matrix is resorbed leads to a sustained process
of healing (Huang, 2010). The integration of this fibrin network into a site for regeneration
facilitates cellular migration, particularly for endothelial cells necessary for neo-angiogenesis and
vascularization (Dohan, 2006). Other benefits include the presence of leukocytes and cytokines in
the fibrin network which can play a significant role in the self-regulation of inflammatory and
infectious processes in areas of regeneration (Simonpieri, 2009). Additionally, the PRF
membrane can offer a structural support and function similar to a fibrin bandage over a wound
and accelerate the healing of the wound edges (Gassling, 2009).
Regenerative endodontics is based on the idea that despite a tooth being classified as
necrotic, some pulpal tissue can survive in the apical region and if conditions are favorable, can
be utilized to proliferate pulpal tissue and accomplish regeneration (Trope, 2010). In
autotransplantation, replantation, and regenerative endodontic therapy, revascularization of the
pulp chamber by ingrowth from the surrounding periapical tissues, passing through the apical
foramen determines the success of these procedures (Laureys et al. 2013). While there is no
standardized method for revitalizing a necrotic tooth, endodontic literature has investigated the
benefits of PRF as an adjunct to apexification and pulpal revascularization. The sustained release
of key growth factors, the trimolecular fibrin scaffold that allows for flexibility, and its ability to
support cytokine enmeshment and cellular migration, are all reasons why PRF has recently gained
attention as an ideal pulp capping material. Shivashankar et al. (2012), Khetarpal (2013), and
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Rudagi & Rudagi (2012) published case reports on PRF in combination with mineral trioxide
aggregate (MTA) in managing cases with open apexes and found accelerated periapical healing
and apical bone formation. In a case report by Shivashankar et al. (2012), treatment of a 9-yearold boy with a fractured immature maxillary central incisor involved irrigation of the accessed
canal with 5.25% sodium hypochlorite and .2% chlorhexidine followed by medicating the
traumatized tooth with triple antibiotic paste for 21 days. After this time period, the paste was
removed, whole blood was drawn from the boy’s arm and used to fabricate PRF, via Choukroun’s
method. The PRF was packed into the canal to the level of the CEJ and MTA was placed over the
top of it. A year later the tooth responded positively to vitality testing and demonstrated
radiographic evidence of continued root lengthening and apex closure.
Shivashankar et al. (2012) cited in vitro studies with PRF and canine and human dental
pulp cells as to why PRF is a choice material for pulpal revascularization. In vitro analysis with
canine pulp cells has corroborated PRF’s ability to promote chemotaxis and proliferation of the
pulp cells and its ability to contribute to pulpal repair (Yang et al., 2013). When PRF was
combined with human dental pulp cells derived from extracted third molars, it did not interfere
with vitality and stimulated proliferation and differentiation. Additionally, it upregulated the
expression of osteoprotegerin and alkaline phosphatase suggesting it may be beneficial in the
formation of reparative dentin (Huang et al., 2010). Expression of these cytokines is usually
regarded as a marker for odontoblastic differentiation. After regression of initial inflammation
associated with an insult, the remaining dental pulp cells in the apical region differentiate into
odontoblast like cells under the influence of Hertwigs Epithelial Root Sheath (Huang et al.,
2010). In the case study by Shivashankar et al. (2012), since no intracanal bleeding was
instigated, regenerated vital tissue can be attributed to the presence of the PRF.
Additionally, PRF has been shown to be compatible with PDL cells. PDL cells are
fibroblast like cells that are characterized by collagen production and some osteoblastic features.
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PDL cells produce numerous cytokines and chemokines in response to promoters of inflammation
(Jönsson et al., 2011). Zhao et al. (2013) investigated PDL cells in combination with PRF to
enhance periodontal healing in an avulsed tooth that has been reimplanted. This study
demonstrated that PDL cells and PRF are compatible and that PRF and PDL cells may enhance
the healing of avulsed teeth.
PRF application: Use in avulsion and tooth transplantation
The clinical utility of PRF and revascularization has also been demonstrated in several
case studies of avulsion (Johns et al., 2013; Keswani et al., 2013; Mishra et al., 2013). These
reports utilized a general protocol of minimally instrumenting the avulsed tooth. Johns et al.
(2013) performed a 3 mm resection of the root apex followed by minimal instrumentation of the
canal. Blood is then drawn from the patient and PRF is prepared via Choukroun’s method. The
PRF is then placed on the root surface and condensed into the canal. The tooth was then
reimplanted, splinted, and the patient followed for up to 24 months. The tooth tested vital to
thermal and percussion testing and radiographically did not show signs of replacement resorption
or inflammation.
The reasoning for the enlargement of the apical foramen was discussed by Andreasen et
al. (1990) in an autotransplantation study involving 370 premolars. It was determined that an
apical foramen of at least 1 mm is required for adequate revascularization of autotransplanted
teeth. It was demonstrated that an apical foramen smaller than 1 mm resulted in unpredictable
revascularization of the pulp tissue and only 15% of mature teeth with closed apices had vital
pulp after transplantation. While the benefits of enlargement of the apical foramen has been
demonstrated, there does not seem to be any precise minimal apical foramen diameter. In a beagle
study, Laureys et al. (2013) saw revascularization with an apical foramen of .32 mm. In a series
of dog studies, Skogland’s group showed that if the apical foramen is enlarged via an
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apicoectomy, mature teeth can be revascularized with a high success rate (Skogland et al. 1981;
Skogland et al. 1978; Skogland and Tronstad 1981). In their studies, control teeth that were
transplanted without apicoectomies did not demonstrate revascularization when evaluated with a
microangiographic technique. In a study by Laureys et al. (2010), 29 beagle teeth with root tip
resections were reimplanted and followed for 90 days. The investigators observed that 80% of
teeth with pulp tissue left in the canal showed 1/3-complete fill with viable pulp tissue, whereas
the group where the pulp tissue was removed prior to reimplantation demonstrated a 79% loss of
viability. The conclusion is that the pulp tissue in the canal assists in stimulating revascularization
and tissue ingrowth through the apical foramen.
Additionally, PRF has been shown to reduce inflammation; an exaggerated inflammatory
process sometimes causes deleterious ankylosis in traumatized teeth. Animal models evaluated
PRF granules combined with human PDL stem cells placed on the root surface of freshly
extracted canine teeth. The teeth were then reimplanted and evaluated histologically after a
healing phase. A regeneration of the PDL-like tissue and reduction in ankylosis and inflammation
were noted in animals with the PRF granules (Zhao et al., 2013). While these studies suggest that
PRF may be a valuable additive in attempting pulpal revascularization after traumatic avulsion of
the adult dentition, more information is needed on its capabilities and limitations. Further study of
cytokine and growth factor components of PRF are needed to determine the proinflammatory and
anti-inflammatory capabilities of PRF. Additionally, a controlled clinical trial in humans with the
reimplantation model utilized by Skogland and Laureys would aid in understanding PRF’s role in
pulpal regeneration in auotransplantation or avulsion cases.
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CHAPTER 3: MATERIALS AND METHODS
Both the in vitro and in vivo portions of the study were approved by the Institutional
Review Board for Human Studies of the University of Nebraska Medical Center (# 443-14-FB)
Clinical Trial:
Investigator Calibration:
Investigator EE underwent a calibration exercise prior to the start of the study. EE
collected 6 extracted healthy teeth with single roots from the College of Dentistry’s
Undergraduate Oral Surgery Department. EE performed an apicoectomy, enlarged the apical
foramen to at least 1 mm (measured with a dental probe), and accessed the pulp chamber
coronally to allow fixation of tissue in accordance to the study design. Teeth were then examined
histologically to ensure that pulpal tissue could be properly fixed and stained. These teeth were
used as baseline controls of ideal pulpal histology.
Study Population and Design:
This study was designed as a prospective randomized, controlled clinical trial. A total of
18 patients were enrolled. Patients receiving treatment at the University of Nebraska Medical
Center College of Dentistry (UNMC COD) that met the inclusion criteria were identified by
investigator EE. The inclusion criteria included any adult (age 19 or older) with single rooted
vital teeth previously treatment planned by UNMC COD prosthodontic faculty for extraction.
These teeth were required to test positive to EPT but not necessarily to thermal. Exclusion criteria
included: uncontrolled diabetics with a reported HBA1c level of 8 or above (taken within the past
3 months), pregnancy, or currently anyone taking or having a history of taking oral or IV
bisphosphonates. A detailed informed consent was obtained from all subjects and all subjects
were given the opportunity to ask questions before signing the consent form.
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Figure 2: Flow of Clinical Study Design
Screening

Eligible patients
identified and invited
to participate (n= 18)

Informed consent
obtained (n=18)

Baseline results
obtained: EPT, cold,
percussion

Stage I- Extract study teeth
(2-3 test and 2-3 control),
Apicoectomy, PRF (Pt.
derived) placed on test.
Splint. (n= 70 teeth)
Teeth removed from
study due to patient
discomfort (n=1)
Stage II- At least 3
months later retest for
EPT, cold, percussion.
(n= 69 teeth)

Extract and
prepare for
histology
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Baseline Evaluations:
Baseline evaluations were recorded to determine the initial vitality status of each tooth.
Current radiographs were evaluated for signs of pathology associated with teeth utilized in the
study. Vitality testing included a yes or no response to percussion, a yes or no response to thermal
testing with Endo Ice (tetrafluoroethane; manufactured by Coltene), and a numerical value for
EPT. If no response was elicited from EPT the value was placed at 80 and teeth were not included
in the study. A hard tissue exam of selected teeth was also performed and caries recorded.
Investigator EE performed all initial baseline evaluations and teeth were analyzed based off of
how many tested positive or negative to each variable (percussion and cold) and then the EPT
changes for all teeth were evaluated.
PRF preparation:
Venous blood (20 mL) was collected from each participant, the PRF was prepared
according to a protocol described by Choukroun by investigator EE. The blood samples were
transferred into two sterile 10-mL glass tubes without anticoagulation and the tubes immediately
centrifuged at 3200 rpm for 12 min in Clay Adams Compact II centrifuge. Three layers were
obtained: the platelet poor plasma, platelet rich fibrin clot, and the red corpuscle layer. The fibrin
clot was easily separated from the red corpuscles at the bottom and divided into thirds with a
sterile 15 blade.
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Figure 3: Fabrication and preparation of PRF

Figure Legend: a) Fabrication of PRF demonstrating the three layers: the platelet poor
plasma, the PRF clot, and the red blood cell layer b) Separation of fibrin clot from other
layers c) Dividing the clot into thirds prior to intraoral placement.
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Surgical Protocol and Root preparation:
After obtaining informed consent, patients received 600 mg of clindamycin
preoperatively. If needed, the teeth were initially debrided with a cavitron if visible plaque and
calculus were present. Teeth were then atraumatically extracted by an oral surgeon (JB). After
extraction, investigator EE performed an immediate root resection of 3 mm with a high-speed
handpiece and a NS NTI super coarse diamond FG Axis (Dental Health Products). The resected
root orifice was then enlarged with a ¼ round bur until the apical diameter was greater than 1
mm. Total out of mouth time was recorded for each tooth.
Application of PRF:
Experimental and control teeth were determined at random via coin toss (performed by
surgical assistant Betty Shestak) during surgery and investigator EE was blind to which teeth
received the PRF intervention. In each patient, between 2-4 teeth were utilized. The PRF was
condensed into the canal and permitted to extrude from the apex. The socket was rinsed with
saline and teeth reimplanted using light pressure. The teeth were splinted to adjacent teeth with
Ribbond (bondable reinforced ribbon, Ribbond, Inc.) and flowable composite for a minimum of 6
weeks. Control teeth received all identical treatments with the exception of the PRF.
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Figure 4: Apicoectomy, placement of PRF, and reimplantation with placement of splint

Figure Legend: a) Tooth preparing for apicoectomy b) Enlargement of apical foramen with ¼
round bur c) Placement of PRF into the apical foramen d) Tooth demonstrating PRF
extruding from apex e) Teeth reimplanted and splinted.
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Follow up:
Patients were followed for a minimum of 3 months and a maximum of 11 months while
their final prostheses were fabricated by UNMC COD dental students. At the end of this period,
teeth underwent the exact same diagnostic testing performed pre-operatively (percussion, thermal,
and EPT) by investigator EE. Teeth were atraumatically extracted and coronal pulpal access
immediately obtained with a 6 mm round bur prior to placing in 10% buffered formalin. The
patients were then followed for a minimum of 2 weeks to ensure healing and completion of their
predesigned prosthetic treatment plan.
Histological analysis:
To obtain a baseline comparison of the histological features of a healthy pulp, 6 freshly
extracted healthy teeth (from the same patient) were obtained from the UNMC College of
Dentistry Predoctural Oral Surgery Clinic. These teeth were utilized to determine the normal
characteristics of a healthy pulp not receiving any study interventions, and to serve as beneficial
comparisons throughout the histological analysis of study teeth.
Histological evaluation was performed by investigators PG and EE (both blind to
research intervention). After extraction, teeth were allowed to remain in formalin for
approximately 1 week. Teeth were then transferred to 5% formic acid for 2-4 weeks depending on
tooth size and time needed to decalcify. Completion of the decalcification process was
determined by cutting the tooth in half at the midline with a new scalpel blade. Halves were then
processed with a Tissue-Tek VIP processor with an overnight program. They were then
embedded in paraffin and sectioned to 6-7 micron cuts with an American Optical Microtome.
Sections were then stained with a routine Mayer’s hematoxylin and eosin (H&E) stain.
Sections were then evaluated microscopically by PG and EE and descriptive histology
recorded for each tooth. Infiltrate (acute, chronic, or mixed), severity (mild, moderate or severe),
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presence or absence of fibroblast nuclei indicative of vital tissue (yes or no), and presence or
absence of blood vessels (none, few, many observed) were recorded for each tooth. Table 2
demonstrates the histological grading scale. If a determination could not be made from the slide,
recuts were ordered until either: a determination of all four variables could be made, or the tooth
was no longer able to be cut on the microtome. In the latter situation, the tooth was determined as
inconclusive and was not utilized for statistical analysis. The histological examination was
performed using a Nikon microscope and digital photomicrographs were obtained using a Nikon
digital camera connected to a Zeiss Axiolab microscope. The system is designed to acquire highdefinition digital images at 10x, 20x, and 40x magnifications.
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Table 2: Histological grading scale
Degree

Stage

Vital Tissue

Blood Vessel

Observed

Observation

Mild

Acute

Yes

None observed

Moderate

Mixed

No

Observed in some slices

Severe

Chronic

Observed in several
slices
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In vitro analysis of IL-6 and PRF:
Study design: group designation and cell culture technique
In the in vitro portion of the study, PDL cells were obtained from ScienCell (Carlsbad,
CA) and grown in complete Dulbecco’s modified Eagle’s culture medium (DMEM) (Life
Technologies, NY) supplemented with penicillin and 10% fetal bovine serum (FBS) at 37 °C in a
humidified 5% CO2, atmosphere incubator.
The following groups were analyzed: Group A consisted of PDL cells and PRF. Group B
consisted of PDL cells, PRF, and LPS. Group C acted as the positive control with PDL cells and
LPS. Group D served as the negative control and consisted of only PDL cells in medium. To
ensure that the cells would adhere to the actual PRF membrane and not just around it on the sides
and floor of the wells, an initial histological evaluation of the membrane was performed. Whole
blood was obtained from one of the healthy subjects and a PRF membrane was fabricated and
then cultured with PDL cells in accordance with the protocol. After culturing for 24 h the
membrane was removed and fixed in formalin, sectioned, and then stained. Histological
evaluation revealed fibroblast attachment directly to the surface of the PRF membrane.
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Figure 5: PRF membrane with PDL cell adherence
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Study design: procedure
Cells between the 4th and 8th passages were used. Whole blood was obtained from two
different healthy subjects and PRF was fabricated according to protocol. PRF was divided into
equal segments and placed in wells of groups A and B of a 24-well plate. A total of 1 x 106 PDL
cells were plated in 96-well plates and cultured overnight in complete DMEM medium to allow
adherence to the surface.
After 24 h, the non-adherent cells were removed from the plates by aspiration and fresh
complete culture medium was added. Cells were then stimulated with 25 ng/mL of LPS (Sigma)
and incubated for 24, 48, and 72 h in 5% CO2 at 37°C and throughout the experiment an equal
volume of fresh medium was added back to each well after collection. All collected culture
supernatants were stored at –80°C before ELISA analysis.
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Figure 6: PRF membranes in culture medium
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Cytokine expression analysis:
Supernatants were analyzed for IL-6 using standard ELISA techniques. ELISA kits
utilized the quantitative sandwich technique. ELISA kits were purchased from eBioscience
(Human IL-6 ELISA Ready-SET-Go! Kit, eBioscience, San Diego, CA, USA). All assay
procedures were completed by one individual (EE). The ELISA tests were performed according
to the manufacturer’s instructions and protocol. Supernatants were allowed to thaw at room
temperature.
100 µL of the standard or supernatant sample was pipetted into each well. Wells were
pre-coated with Anti-Human IL-6 antibody. Samples and standards were then covered with a
plate sealer and allowed to incubate overnight at 4 °C. All wells were then aspirated and washed a
total of 5 times with wash buffer (1x PBS, 0.05% Tween-20). Following the wash, 100 µL of IL6 conjugate was added to each well. The samples were again covered and incubated for 1 h at
room temperature. Aspiration and washing was again performed 5 times. 100 µL of enzyme
solution (Pre-titrated Avidin-HRP) was added to each well. The samples were again covered and
incubated for 30 minutes at room temperature. Aspiration and washing was again performed 7
times. 100 µL of substrate solution was added to each well. The samples were then covered and
incubated at room temperature for 15 minutes and protected from light. 50 µL of stop solution
was added to each well and gently agitated until uniform color was obtained. Absorbances were
read using a microplate reader ELx808 (BioTek). The plate was read at a 450 nm wavelength and
corrected for optical imperfections using 570 nm wavelength readings subtracted from the 450
readings. All readings were completed within 30 minutes of the addition of the stop solution.
Standard calibration curves were generated using computer software and a regression
analysis. Concentrations were then calculated and expressed as total weight of molecules by
picograms/milliliter (pg/ml) for IL-6. For each experiment, means and standard deviations were
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calculated and statistical significance between groups was analyzed. The minimum detectable
concentration for the ELISA was less than 0 pg/mL and the maximum detectable concentration
was 45,635.75 pg/mL. All samples were analyzed separately and in duplicate. The standard curve
was used to estimate the concentration of each sample. If a sample tested at a level lower than the
minimum detectable concentration, it was reported as 0 pg/mL.
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Figure 7 ELISA samples demonstrating IL-6 identification

Figure Legend: a) Samples placed in wells. b) Samples and standards after substrate was
added c) Samples and standards after stop solution.
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Analysis of IL-6 expression in PRF membrane:
In an effort to minimize error, the release of IL-6 from the PRF membrane itself was
analyzed. After fabrication, the membrane itself was separated into 12 pieces approximately 0.5
cm x 0.5 cm and placed in ELISA well plates. From another membrane, liquid was expressed
immediately after fabrication and pipetted into 12 wells and the ELISA performed to analyze PRF
independent release of IL-6 so that any background release by the membrane could be considered
in group analysis.
Statistical analysis
Before initiation of the study, a power analysis was completed. Based on previous
studies, it was anticipated that 50% of control teeth would be classified as vital and 79% of test
teeth would be classified as vital. Using these criteria, power analyses were performed, and a
proposed sample size of 20 patients with 4 teeth each (80 teeth) was determined. We expected 20
subjects to enroll in the study, with 4 reimplanted teeth per person, 2 PRF and 2 control teeth
(giving a total of 80 teeth, 40 randomized to PRF and 40 randomized to control). With 80 teeth
we can detect a difference of 32% in vitality (82% vitality in the PRF group vs. 50% vitality in
the control group) with 90% power and an alpha level of 0.05. The test statistic used for the
power calculation is the two-sided Z test (unpooled). The sample size calculation was performed
using NCSS and PASS.
Patient characteristics were tabulated using frequencies and percentages for categorical
variables and median and range for age. Linear mixed models were used to look at the effect of
treatment on EPT pre-treatment, post-treatment and at changes over time. Compound symmetry
structure was used for the covariance matrix, based on Akaike information criteria. This model
allows for correlation due to multiple teeth examined in each person. Generalized linear mixed
models (GLMM) were used to look at the proportion positive for thermal and percussion tests as
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outcome variables both pre-treatment, post-treatment and at changes over time. For the models
considering treatment and time, interactions were considered. Multivariate models were also
examined looking at the treatment effect after adjusting for age, gender, race, smoking status,
diabetes and duration of treatment. SAS software version 9.3 was used for statistical analysis
(SAS Institute Inc., Cary, NC).

38

CHAPTER 4: RESULTS
Clinical Trial:
Patient characteristics:
A total of 18 subjects were enrolled in the study with a total number of 70 teeth. One
tooth was lost to the study due to the need for early extraction for patient comfort. The median
number of treated teeth per person is 4 and ranged from 2 to 6. Half of the teeth were randomized
via coin flip to PRF treatment and half to no PRF treatment. To prevent imbalances between
treatment groups and improve the power for the small sample size, patient stratified
randomization was utilized. Patients were followed for a minimum of 3 months and a maximum
of 11 months. Throughout the treatment period, 5 out of 18 patients (28%) required a single postoperative week of clindamycin (300 mg taken three times daily for 7 days) upon presenting with
signs of infection. During the course of the study one patient reported an increased HBA1c from
previously under 8 (in accordance to inclusion requirements) to 10.7. It was decided to not
exclude this patient from the study, but to include this in the statistical considerations. Patient
characteristics are shown in Table 3 below.
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Table 3: Patient characteristics at baseline

There was no statistical significance between groups for baseline diagnostic tests
including EPT, thermal, and percussion. Table 4 depicts the mean diagnostic tests for both the
control and test groups.
Table 4: Pre-treatment tooth characteristics

Clinical outcomes:
There was no statistically significant difference between groups for any of the vitality
readings post operatively. EPT, thermal, and percussion means per group are depicted in Table 5.

40

Table 5: Post-treatment tooth characteristics

During the initial intervention PRF treated teeth were out of the mouth for a longer
amount of time in comparison to the control teeth and this difference in out of mouth time was
statistically significant (p=0.035). Table 6 shows the mean out-of-mouth time and its statistical
significance.
Table 6: Out of mouth time per treatment group

Diagnostic test: EPT
Changes in EPT over time (pre vs post) were evaluated by treatment group, using a linear
mixed effects model. There was not a significant interaction between treatment and time (p=0.86)
indicating that the effect of treatment did not differ over time. It was also noted that on average
EPT did not differ by treatment vs. control (p=0.56). Both groups saw a significant increase in
EPT from pre- to post-treatment (p<0.0001). On average, the post-treatment EPT is 22.7 higher
than the pre-treatment EPT. Table 7 shows the diagnostic EPT values for both groups and Figure
8 depicts these changes.
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Table 7: Changes in EPT over time

Figure 8: Changes in EPT over time by group
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A multivariate model of changes in EPT over time was utilized. Again, interactions
between treatment and time were not significant; therefore, it was excluded from the model. As
seen in Table 8, the multivariate model showed females have lower levels of EPT on average by
16.7, and a significant increase in EPT over time. The interaction between treatment and time out
of the mouth was not significant (p=0.11). Time out of the mouth significantly increases EPT on
average by 6.1 (p=0.008).
Table 8: Multivariate model of changes in EPT over time.

Diagnostic test: thermal
Changes in thermal over time (pre vs post) by treatment group were evaluated, using a
GLMM. The link function was legit, but results were backtransformed to the original scale and
can be interpreted as proportion positive. Show in Table 9 and depicted by Figure 9, there was not
a significant interaction between treatment and time (p=0.45) indicating that the effect of
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treatment on thermal did not differ over time. It was also noted that on average, thermal did not
differ by treatment vs. control (p=0.30). Both groups saw a significant decrease in proportion
positive for thermal from pre- to post-treatment (p=0.014). On average the post-treatment thermal
proportion is 0.30 lower than the pre-treatment proportion.
Table 9 Changes in thermal over time

Figure 9 Changes in thermal over time by group
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A multivariate model of changes in thermal over time was then evaluated, represented in
Table 10, here on the logit scale. Again, interactions between treatment and time were not
significant, therefore it was excluded from the model. Again, time out of mouth was found to be a
statistically significant variable (p= 0.039). Proportional thermal change was significant over
time, and decreases with time out of the mouth.
Table 10: Multivariate model of changes in Thermal over time (data on the logit scale)

Diagnostic test: percussion
Next, changes in percussion over time (pre vs post) by treatment group were looked at
using a generalized linear mixed effects model. The link function was logit, but results were
back-transformed to the original scale and can be interpreted as proportion positive. Percussion
did not differ significantly over time or by treatment as can be seen by Table 11 and depicted by
Figure 10.

45

Table 11. Changes in percussion over time

Figure 10. Changes in percussion proportion positive over time by group
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A multivariate model of changes in percussion over time was then performed, here on the
logit scale. Again, interactions between treatment and time were not significant; therefore, it was
excluded from the model. Percussion did not differ significantly by any of the study variables as
seen in Table 12.
Table 12: Multivariate model of changes in percussion over time (data on the logit scale)

Histological outcomes:
Comparison of histological grading:
After removing teeth that were determined to be inconclusive histologically, histology
data was available on 62 teeth. There was no statistically significant difference between PRF and
the control group for inflammatory type, grade, evidence of vitality (nuclei in pulpal tissue), or
presence of blood vessels. Table 13 has basic chi-square tests at the tooth level demonstrating
these results.
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Table 13. Post-treatment tooth characteristics – histology (at the tooth level)
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Next, the multivariate model GLMM was utilized to evaluate evidence of vitality. Table
14 presents odds ratios (OR) and 95% confidence intervals. Vitality was not associated with any
patient characteristics. Older age was marginally associated with evidence of vitality
Table 14: Multivariate model of evidence of vitality

The following section includes the descriptive histology that was observed for the healthy
control teeth not involved in the study, teeth not receiving PRF (the control group), and teeth
receiving PRF (the test group).
Healthy control teeth from patients not receiving study interventions:
The vessels were primarily centrally located and ran in a longitudinal direction from the
enlarged apical foramina to the coronal pulp chamber. A well-vascularized, cell-rich connective
tissue was observed in the apical areas of the pulp chambers. The larger blood vessels were
centrally located and surrounded by smaller intermediate sized vessels. Histologically, a normal
pulp tissue with a regular odontoblastic layer was observed.
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Figure 11: Example of vital pulp from a healthy freshly extracted tooth not having received
study interventions (10x)
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Descriptive histological results for teeth without PRF (Control) and teeth with PRF (test):
There were teeth that exhibited signs of vitality and teeth that were apparently necrotic in
both groups. The teeth that appeared to be necrotic exhibited significantly less signs of normal
vital pulp including a generalized lack of vascularity, less organization of pulpal tissue,
disorganized collagen, tissue without apparent nuclei, and a greater inflammatory infiltrate. Some
tissues were either poorly stained or so minimal in quantity that it was not discernable.
Frequently, only fragments of cells and necrotic collagen were found. When an infiltrate was
observed, the majority of teeth exhibited an extensive neutrophilic presence with occasional signs
of chronic inflammation distinguishable by the presence of plasma cells and lymphocytes.
The teeth that were determined to be vital had the following characteristics. These teeth
were seen to generally have more organized collagen throughout the chamber with vitality
evident through the presence of cellular nuclei. Areas of vascularization were mostly located in
the apical region of the pulp canal for the majority of teeth; however, in many teeth the blood
vessels had proliferated throughout the pulp chamber. The area of vascularized pulp tissue varied
in size depending on the tooth. When blood vessels were observed in the chamber, they
resembled the control teeth examined prior to the study. The vessels were usually primarily
centrally located and ran in a longitudinal direction from the apical foramina to the coronal pulp
chamber. A well-vascularized, cell-rich connective tissue was observed throughout the pulp
chambers. The larger blood vessels were centrally located and surrounded by smaller
intermediate sized vessels. Histologically, a normal pulp tissue with a regular odontoblastic layer
was usually observed. In some cases, a mild infiltrate was observed. In teeth that were determined
to be vital, there was most frequently either no infiltrate or acute inflammation distinguishable by
neutrophils. Figures 12 and 13 depict the variety of histological that were observed with both
control and test teeth respectively.
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Figure 12: Histological images of teeth not treated with PRF (Control) representative of
sample of n=34

Figure Legend: a) Control tooth demonstrating pulp stones and blood vessels in a specimen
present in the mouth for 3 months (10x). b) Control tooth demonstrating blood vessels in a
specimen present in the mouth for 3 months (10x). c) Control tooth demonstrating blood
vessels, nuclei, and local infiltrate, in a specimen present in the mouth for 3 months (10x). d)
Control tooth demonstrating blood vessels, nuclei, and pulp stones in a specimen present in the
mouth for 3 months (10x).
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Figure 13: Histological images of teeth treated with PRF (Test) representative of sample of
n=35

Figure Legend: a) Test tooth demonstrating vital pulp tissue in a specimen present in the
mouth for 3 months (40x). b) Test tooth demonstrating endothelial lined blood vessels in
a specimen present in the mouth for 11 months (20x). c) Test tooth demonstrating vital
blood vessels in the pulp chamber of a specimen present in the mouth for 5 months (10x).
d) Test tooth demonstrating vital blood vessels in the pulp chamber of a specimen present
in the mouth for 5 months (40x). e) Test tooth demonstrating necrotic pulpal debris of a
specimen present in the mouth after 4 months (5x).
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Statistical analysis of histological results and clinical diagnostic tests:
Again a univariate GLMM model was utilized to evaluate evidence of vitality, looking at
associations with pre diagnostic tests and vitality. Vitality was associated with Pre EPT but not
with any other variable prior to the study. A one-unit increase in EPT is 5% more likely to have
evidence of vitality (p=0.054).
Table 15: Evidence of vitality based on pre-diagnostic tests

Lastly, the univariate GLMM model was again utilized while looking at the associations
with post diagnostic tests and vitality. Vitality was not associated with post diagnostic tests.
Table 16: Evidence of vitality based on post-diagnostic tests

In vitro analysis of IL-6 and PRF outcomes:
ELISA results between groups Group A (PDL+PRF), Group B (PDL + LPS +PRF),
Group C (PDL + LPS), and Group D (PDL only), at three time points. Table 17 expresses the
means and standard deviations of each group at time points 24, 48, and 72h.
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Table 17: ELISA data in pg/ml of IL-6

At 24 hours there is an overall significant difference between the groups by Kruskal-Wallis
test (p=0.0004). Wilcoxon rank sum test was used to conduct pairwise comparisons. Table 18
contains the pairwise comparison p-values between the groups at 24 h, adjusted for pairwise
comparisons with Bonferroni’s method. The high standard deviation for Group A is likely due to
laboratory error. Figure 14 graphically represents these comparisons.


PDLs concentration is significantly lower than the group with LPS+PRF and the LPS
only group.



The LPS only group concentration is significantly different (lower) than the group with
LPS+PRF

Table 18: 24-hour culture group IL-6 production comparison
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Figure 14: 24-hour mean pg/ml concentrations PDL cells
24 Hours Mean pg/ml Concentrations
PDL cell
45000
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pg/ml IL-6

35000
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0
PDL Only

PDL + PRF

PDL+LPS

PDL+LPS+PRF

CULTURE CONDITION

Figure legend: Same number of * indicates no difference between groups.
Different number of * indicates statistical significance between groups.
Between PDL+LPS+PRF and PDL+LPS (p<0.031). Between PDL+LPS+PRF
and PDL (p<0.03). Between PDL+LPS and PDL (p<0.03).

At 48 hours there is an overall significant difference between the groups by Kruskal-Wallis
test (p=0.0003). Wilcoxon rank sum test was used to conduct pairwise comparisons. Table 19
contains the pairwise comparison p-values between the groups at 48 h, adjusted for pairwise
comparisons with Bonferroni’s method. Figure 15 graphically represents these comparisons.


The PDLs concentration is significantly lower than all other groups



The LPS only group concentration is significantly different (lower) than the LPS+PRF
group.



The PRF only group concentration is significantly different (lower) than LPS+PRF
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Table 19: 48-hour culture group IL-6 production comparison

Figure 15: 48-hour mean pg/ml concentrations PDL cells
48 Hours Mean pg/ml Concentrations
PDL cell
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Figure legend: Same number of * indicates no difference between groups.
Different number of * indicates statistical significance between groups.
Between PDL+LPS+PRF and PDL+PRF (p<0.049) and PDL and PDL+LPS
(p<0.031). Between PDL+PRF and PDL (p<0.049). Between PDL + LPS and
PDL (p<0.031).
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At 72 hours there is an overall significant difference between the groups by Kruskal-Wallis
test (p=0.0006). Wilcoxon rank sum test was used to conduct pairwise comparisons. Table 20
contains the pairwise comparison p-values between the groups at 72 h, adjusted for pairwise
comparisons with Bonferroni’s method. Figure 16 graphically represents these comparisons.


The LPS+PRF group concentration is significantly different (higher) than all other
groups.

Table 20: 72-hour culture group IL-6 production comparison
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Figure 16: 72-hour mean pg/ml concentrations PDL cells

Figure legend: Same number of * indicates no difference between groups.
Different number of * indicates statistical significance between groups.
Between PDL+LPS+PRF and PDL+PRF and PDL (p<0.049). Between
PDL+LPS+PRF and PDL+LPS (p<0.031).

The averages over time show an overall significant difference between the groups by
Kruskal-Wallis test (p<0.0001). Wilcoxon rank sum test was used to conduct pairwise
comparisons. Table 21 contains the pairwise comparison p-values between the groups, adjusted
for pairwise comparisons with Bonferroni’s method. Figure 17 graphically represents these
comparisons.


All groups are significantly different from each other, except for the groups with only
PRF and only LPS.
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Table 21: Average 24-72 hour culture group IL-6 production comparison

Figure 17: Average pg/ml of IL-6 from 24-72 hours
Average 24-72 Hours Mean pg/ml
Concentrations
PDL cell
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Figure legend: Same number of * indicates no difference between groups.
Different number of * indicates statistical significance between groups
(p<0.001).

Evaluating each individual group’s change over time showed that the PRF only group
did not statistically change over time (p=0.83) by using the Kruskal-Wallis test. The LPS+PRF
group also did not significantly change over time (p=0.13). The LPS only group decreased over
time (p=0.0011), and the PDLs increased over time (p=0.0017). Figure 18 graphically depicts
these group comparisons.
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Figure 18: Averages of groups in pg/ml of IL-6 over 24-72 hours

Changes per Group Over 24 -72 hr (pg/ml)
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Figure legend: The PRF only group and the LPS+ PRF groups did not significantly change over time. The
LPS only group decreased over time. The PDLs increased over time. The * indicates a statistically
significant change between the 24-72 hour periods.

Evaluation of the PRF membrane and expressed liquid revealed that IL-6 release
within 24 h of membrane preparation was negligible and therefore, did not interfere with group
concentrations.
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CHAPTER 5: DISCUSSION
This single-blinded randomized controlled clinical trial evaluated the effect of PRF on
pulp vitality after atraumatic extraction, root resection, and immediate reimplantation for a period
of 3-11 months. Every precaution was taken to eliminate any bias by compartmentalizing the
various aspects of the study protocol as follows: blind examiner (EE) collected baseline and final
diagnostic data, fabricated PRF, performed the root resection, and recorded histological results
dictated by pathologist. Clinician (JB) performed extractions and randomization of PRF
application, but was blind to diagnostic data and histological findings until study completion.
Investigator (PG) evaluated histological specimens while blind to any patient information,
diagnostic data, or tooth treatment. While patient selection, and furthermore tooth selection
within those patients, was severely limited by the poor condition of their oral health, teeth were
selected that permitted little to no baseline differences between treatment groups. These
differences resulted in no statistical significance in baseline parameters. Pre EPT values were
33.1 (+/- 3.0) and 34.0 (+/- 3.0) for control and PRF teeth respectively. Pre thermal values
demonstrated that 93.9% (+/- 4.8) of control and 85.2% (+/- 8.9) of PRF treated teeth responded
positively to cold. During the study, 28% of patients required a post-operative week of
clindamycin due to symptoms of infection; however, the multivariate analysis did not find any
correlation between any other variable.
We found that the addition of PRF did not significantly impact any measured variable when
compared to the non-PRF controls. There are numerous points to consider while interpreting
these results. Firstly, vitality of control teeth was not an unexpected outcome. In Skoglund’s
research, the series of studies showed that if an apicoectomy procedure is used to enlarge the
apical foramen, revascularization of mature teeth after transplantation is possible and has a high
success rate. Therefore, the intention of the present study was to evaluate if PRF enhanced these
results in mature teeth. The present study showed similar histological results for both groups as
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did the apicoectomy histology of the Skoglund series, emphasizing that enlargement of the apical
foramen may be enough to encourage regeneration. An additional finding in the Skoglund series
suggests a possible reasoning for the decreasing trend in vitality parameters observed in the
present study. Skoglund et al. (1981) discussed that widening of the apical foramen with a bur is
not as successful as the method they chose in their study, which was enlargement with a wire
cutter. As the methods in the present study involved a bur for the apicoectomy, it is possible that
this encouraged more inflammatory response than the wire cutter in Skoglund’s study. This may
be one reason why both groups saw a significant increase in EPT (average of 22.7 EPT points
higher post-treatment) and decrease in thermal response (30% lower) from pre to post vitality
recordings.
Next, a discussion on subject complications is necessary. Subject recruitment proved to be
challenging due to the specific requirements of the study and the general nature of the dentition of
many patients presenting to the dental school in need of full or partial dentures. Therefore, the
original N of 20 subjects with 80 study teeth was not attainable in the restricted time for the
study. Instead, an N of 18 subjects with 69 teeth were evaluated. This 14% reduction may have
kept some of the measurement parameters from achieving statistical significance. Additionally, 7
of these teeth were determined ‘inconclusive’ histologically and could not be utilized for
histological evaluation.
Next, one must consider the state of the teeth and periodontium of the subjects in this study.
Autotransplantation can be highly successful especially in teeth without fully developed roots
(ideally no more than two thirds of its final length) and if it is moved atraumatically to a suitable
receptor site with minimal out-of-mouth time. The receptor site should be wide enough and free
of inflammation to enhance results (Laureys et al., 2013). In the present study, due to the limited
patient pool as well as the nature of the dentition in most patients electing full dentures, the teeth
and corresponding periodontium were not ideal. Laureys et al. (2013) notes that absence of
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inflammation can improve the results of autotransplantation; however, most of the subjects in the
present study had significant inflammation, minor to severe carious lesions, significant occlusal
wear, and periodontal disease limiting the support for the reimplanted teeth.
In addition to the initial substandard condition of the subjects’ dentition, it became apparent
that in many cases the state of occlusion would be impossible to manage. During the healing
process, it is important that the tooth is not traumatized as occlusal forces can expand the
inflammatory response and lead to fibrous tissue formation in the pulp tissue (Hasegawa et al.,
2007). This could be a contributing factor in some subjects whose teeth maintained less vitality
than others. As these patients were undergoing the process of denture fabrication, many of them
were in a state of considerable malocclusion and had few remaining teeth; therefore, attempts
were made to minimize occlusal discrepancies but ideal was not always achievable. In many
cases due to loss of vertical dimension, malocclusion, or limited remaining teeth for mastication,
the subjects continued to function on the study teeth and the teeth were unable to be removed
from traumatic occlusion.
A second occlusal issue that arose was patients with nocturnal parafunctional habits such as
bruxing and clenching. It was observed that these patients experienced considerably more postoperative discomfort than other study patients, and likely resulted in more trauma to the study
teeth throughout the observation period. The results from the histological analysis further pointed
to the importance of minimal occlusal trauma. Many of the individuals who had more than one
non-vital tooth (either control or test) at the end of the study were patients that presented with
multiple post-operative complications due to nocturnal parafunctional habits. One individual had
six teeth that were utilized for the study and all six, regardless of treatment, responded non-vital
to diagnostic testing and were all observed to be necrotic histologically. This individual had the
most post-operative appointments and reported significant pain while sleeping and had a history
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of bruxing and clenching. Additionally, patients that had only one arch of dentition remaining,
therefore no opposing dentition, were observed to have fewer complications throughout the study.
A factor found to be more critical than the application of the PRF was the amount of time it
took to complete the intervention to the tooth and therefore, the amount of time the tooth was out
of the mouth. In this study, the average out of mouth time for control teeth and PRF treated teeth
was 1.62 (+/-.11) and 1.88 (+/- .11) minutes respectively; this was statistically significant (p=
0.035). Out-of-mouth time is another important feature to consider in the success of the
reimplantation (Andreason et al., 1981; Andreason et al., 1990). The out-of-mouth time should be
kept at a minimum through quick handling and efficient execution of the procedure steps
(Laureys et al., 2013). In the present study, the out-of-mouth time was longer for teeth receiving
the intervention. This resulted in a statistically significant relationship with post EPT (p=.0090)
and thermal values (p=.0039). Better results for PRF treated teeth may have been observed if
out-of-mouth time for PRF treated teeth and control teeth had been similar. When investigating
pulpal revascularization and vitality, it may benefit future studies to focus more on the out of
mouth time for tooth transplantations than on the different interventions to the root surface.
In addition, there was also subject bias that came into play regarding the accuracy of the
results. Due to the nature of the diagnostic testing it is difficult to determine a simple yes or no
vitality reading. Percussion is suggestive of pressure in the PDL or possibly traumatic occlusion,
but does not give a clear answer regarding vitality. Thermal testing can be misleading as many
individuals have vital teeth that all test negative to cold. EPT can allow the investigator to
evaluate trends, but it is difficult to determine complete loss of vitality. Additionally, with
regeneration, vitality diagnostic testing is not always predictable. Peters (2014) noted that it is
unlikely there will be a positive response to cold or electrical stimuli in all cases of regeneration.
This was verified histologically, as there was no correlation found between post-operative
diagnostic testing and histological evidence of vitality; however, there was a correlation with pre-
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diagnostic EPT tests (p=0.054). This suggests that teeth with high EPT values to start with had a
higher chance of being vital at the end of the study. This was difficult to evaluate; however, as
subjects were frequently not consistent in when they informed the investigator (EE) they felt the
stimulus. For example, sometimes they would inform upon experiencing any response to stimulus
and then would not respond unless it was to a certain ‘strength’ or ‘discomfort’ level they were
expecting. It also became apparent that subjects may be withholding honest answers in efforts to
sway the results in one direction or the other. Even though investigators did not inform the
subjects on what responses were positive or negative, it was apparent to the investigator that some
desired a successful result and tried to provide that. This may have led to some bias in reporting
the diagnostic test results, therefore, it is crucial that histology was also available for examination.
For these reasons, it was beneficial that the study additionally included evaluation of the
histological state of each study tooth. Some difficulties were encountered in this aspect of the
study as well. As many of the teeth were not in ideal condition and many were small mandibular
incisors, it was frequently difficult to obtain a clean view of the pulp chamber. If pulp tissue was
not seen on initial cuts, recuts requesting deeper sections were ordered. After multiple recuts and
sometimes reorientation of the teeth, the pulp chambers could still not be found. This led to 7
teeth (10% of samples) being labeled as inconclusive and histological data could not be submitted
for statistical analysis on these teeth. From the histological patterns noted, it appears that repair of
the pulp occurs through the proliferation and migration of cells from the recipient bed in the
periapical region and moves upward towards the coronal aspect of the pulp canal. This is in
accordance with other autotransplantation studies (Skoglund et al., 1998; Laureys et al., 2010).
Despite the teeth having been in the mouth for a period of at least 3 months, if there was
inflammatory infiltrate present it was frequently observed as acute or mixed (52% of samples).
This may have been related to the IL-6 present in the PRF membrane; given that IL-6 extends the
period of acute inflammation before finally assisting in the transition to chronic inflammation
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(Gabay et al., 1997). While 40% of the samples presented with no observable inflammatory
infiltrate and only 8% demonstrated chronic inflammation, it is plausible that the PRF was aiding
in prolonging the acute inflammatory response. As the PRF was placed based off of a coin flip,
the teeth receiving the PRF may not have been very far apart and therefore, the benefits of the
PRF may have extended to the control teeth which is why no observable difference was noted
between groups for either diagnostic testing or histological analysis of regeneration. A split
mouth design may not be reasonable when utilizing a material with the potential to measurably
affect the inflammatory response so drastically. It is unlikely it remained localized to only the
tooth apex to which it was applied. Regardless, after evaluation of both the diagnostic test results
as well as the histologic data, the initial clinical hypothesis must be rejected. Ultimately, PRF did
not enhance the regeneration of teeth in the treatment group over the control group.
Regarding the IL-6 in vitro results, it was observed that in contrast to the initial
hypothesis, PRF synergized with LPS in stimulation of IL-6 from human PDL cells. A one-way
analysis of variance (ANOVA) test was conducted. An ANOVA has 4 assumptions:
independence, normality, linearity, and equal variance between groups. Because model
assumptions were violated with the in vitro data (normality and equal variance) and
transformations did not fix the violations, non-parametric tests were used for comparisons.
Analysis was done of the data at each time point and for all the time points combined. A KruskalWallis test was used to look at overall group differences. Pairwise comparisons were conducted
with the Wilcoxon rank sum test and were adjusted for multiple comparisons using Bonferroni’s
method. SAS software version 9.3 was used for statistical analysis (SAS Institute Inc., Cary, NC).
Throughout the experiment from 24-72 h, the PRF+LPS group maintained a statistically
significant (p<.001) higher concentration of IL-6 when compared to all other groups. The PRF
only group behaved essentially like the LPS only group and demonstrated no statistical
significance throughout the observed time period indicating that PRF and LPS are similar in their
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abilities to stimulate the production of IL-6 from PDL cells in culture. Several considerations
must be taken into account in interpreting these results. Firstly, PRF liquid contained negligible
IL-6, which is in accordance with published literature on initial cytokine release from a PRF
membrane (Dohan et al., 2009). Dohan et al. (2009), demonstrated that the initial extracted
amounts of growth factors soon after membrane preparation was always significantly lower than
the released total amounts from the membrane itself when tested after 7 days of incubation.
Therefore, through determining the initial release of IL-6 from the PRF membrane to be
negligible, it can be inferred that the IL-6 expression observed in the present study is a product of
stimulation from the PDL cells in culture.
While there was no IL-6 detectable after 24 h in the PRF membrane or the liquid
immediately expressed from the membrane, it is plausible that there may have been additional
release over an extended period of time. In a study by Dohan et al. (2009), PRF membranes and
the liquid expressed from them shortly after fabrication were analyzed for 4 main cytokines via
ELISA. Over 200 h, cytokines TGFβ1, VEGF, PDGF-AB, and TSP-1 were evaluated in time
intervals, and all but VEGF demonstrated similar release patterns with a quick release during the
first 24 h and then a slow down around day 2 and finally a steady state of slow release up until
day 5. VEGF showed an increased release during the initial 4 h and then followed the trends of
the others. This demonstrates that PRF does release cytokines into the environment, even without
provocation.
From the results of the present study it is evident that IL-6 does not follow a similar quick
24-hour release; however, we do see a similar trend (though not statistically significant) in the
amount of IL-6 expressed by PDL cells at 24-72 h suggesting that the pro-inflammatory cytokines
released from the PRF membrane evokes IL-6 production by the PDLs which peaks early on and
then holds a relatively steady state with minor decline over the next two days. This demonstrates
the known slow steady release of cytokines previously shown with PRF; had the study been
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extended, there may have been a larger drop observed later. In a study by Su et al. (2009), the
growth factor concentrations of PRF were analyzed and shown to increase in concentration in
solution from 5 to 300 minutes. While the investigators did not analyze IL-6, it is plausible that
its expression from the PRF membrane also increases over time. This slow sustained release of
IL-6 and other pro-inflammatory cytokines evoking IL-6 release is a plausible reason for the
observed increase in this cytokine over the course of 72 h in the present study. When considering
an in vivo model, this may become an active player between 1-2 weeks after application. If the
period of study had been extended, a continued decreasing trend in the production may have been
observed.
Additional considerations for these results must include a discussion on the quantity of
IL-6 observed in the laboratory environment versus the differences in the biological environment
of the human mouth. Dohan et al. (2009) states that immediately after application of PRF, the
platelets are activated and drastically evoke cytokine and growth factor release from neighboring
cells during the first few hours after application. It is likely that the time frame of the current
study captured this massive release of cytokines that elicited IL-6 production from the PDL cells,
which initially ramped up cell inflammation but then began to taper off, and likely a steady state
would have been reached. In the present study’s closed system, this trend is straightforward;
however, when utilized in a human body the multifactorial nature of these interactions become
complicated. One such consideration involves the leukocyte concentration of the PRF.
Choukroun’s PRF is a leukocyte-rich form of PRF, meaning that leukocytes are not separated out
during the fabrication process. The presence of leukocytes in the formulation has been suggested
to influence the observed pro-inflammatory effects through the proteases and acid hydrolases
contained in white blood cells (Anitua et al., 2007). This factor also may have perpetuated the
release of IL-6 in the closed PDL cell environment in the present study; however, the leukocytes
may have added many additional benefits that outweigh their pro-inflammatory characteristics in
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an in vivo model. The presence of these leukocytes may have assisted in resolving the
inflammation for the 40% of teeth that histologically demonstrated no inflammatory infiltrate.
It has to be acknowledged that the behavior of the leukocytes and the PRF membrane
itself in a less diluted medium may also be different. Dohan et al. (2009) points out that by
placing the PRF membranes in DMEM, it creates a massive call for cytokine release due to
dilution related concentrations. Therefore, it is possible that in a physiological situation, the actual
release profile in the biological environment may differ. In addition to this, aside from the actual
cytokine release, one must also consider how the biological environment may respond to other
components of the PRF fibrin mesh. Hotwani & Sharma (2014) indicate that there are several
cytokines within the PRF matrix that modulate inflammation and act as anti-inflammatory
counterparts to the pro-inflammatory cytokines present. IL-4, for example, assists in reducing
inflammation through decreasing the production of cells that are major players in tissue
destruction and propagation of the inflammatory response. Simonpiere et al. (2009) note that
platelet cytokines PDGF, TGF-α, IGF-1 are gradually released as the fibrin matrix is resorbed,
which allows a perpetual process of healing through neoangiogenesis and the formation of
connective tissue components. Therefore, the nature of the inflammatory process and the
complexity of the interactions occurring in vivo must be taken into account when interpreting the
synergistic effect of PRF and LPS on IL-6 release.
A certain amount of inflammation is necessary and required for the healing process,
therefore some stimulation of IL-6 by PRF can actually be a benefit in a biological environment.
The anti-inflammatory properties of IL-6 can assist in extending the acute inflammatory period
(Barnes et al., 2011). This, along with other anti-inflammatory cytokines released from PRF, may
assist in vivo in reducing the tissue destruction during remodeling after tooth avulsion or
transplantation. Additionally, the angiogenic properties of IL-6 through stimulation of VEGF
from fibroblasts, as well as prevention of collagenolysis through the upregulation of TIMP-1,
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may make IL-6 a valuable presence for the promotion of tissue healing (Mihara et al., 1995; Jones
et al., 2005). Therefore, when considering both the beneficial aspects of IL-6 along with the PRF
membrane’s release of anti-inflammatory cytokines and ability to evoke other anti-inflammatory
modulators from cells in the surrounding tissues, the other components within the membrane may
counteract this seemingly large amount of IL-6 evoked by PRF and LPS in this study. IL-6 may
have been a benefit in this present study’s clinical arm where it may have helped to prolong the
acute inflammatory response for all teeth in the area, both test and control, as well as promote
new vessel growth and regeneration.
Therefore, from the results of the present study, it is apparent that the initial hypothesis
must be rejected. Rather than reducing the inflammatory response, it can be concluded that PRF
unequivocally elicits stimulation of IL-6 from PDL cells. Taking the previously mentioned
factors into consideration it is likely that IL-6 concentrations in this cell culture study are inflated
from what may actually be occurring when a PRF membrane is utilized by a dentist to promote
intraoral healing or by a physician to overcome a patient’s chronic non-healing ulcer.
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CHAPTER 6: CONCLUSIONS
The addition of PRF does not improve the diagnostic tests (EPT, thermal, or percussion)
or the histological evidence of vitality of an autotransplanted tooth when compared to
apicoectomy and foramen enlargement alone. However, more benefit may be seen with the use of
PRF in cases where trauma from occlusion can be ideally managed. Future studies may benefit
from evaluating the effects of out of mouth time in regards to autotransplanted teeth and vitality
testing. Additionally, PRF was found to synergistically enhance IL-6 production from PDL cell
cultures when combined with LPS. The overall effects of this production may be diminished in
vivo when considering the other anti-inflammatory cytokines produced in response to IL-6.
Evaluating multiple pro and anti-inflammatory cytokines in the PRF membrane may be beneficial
for future studies.
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